Insider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells $282,115.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson sold 8,500 shares of BridgeBio Pharma stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $33.19, for a total transaction of $282,115.00. Following the sale, the chief financial officer now directly owns 102,464 shares of the company’s stock, valued at $3,400,780.16. This represents a 7.66 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

BridgeBio Pharma Trading Up 1.9 %

Shares of NASDAQ BBIO opened at $34.90 on Friday. The company has a fifty day moving average price of $32.68 and a 200 day moving average price of $28.32. The firm has a market cap of $6.64 billion, a PE ratio of -12.25 and a beta of 1.07. BridgeBio Pharma, Inc. has a 1-year low of $21.62 and a 1-year high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO) last posted its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The firm had revenue of $5.88 million during the quarter, compared to the consensus estimate of $4.04 million. Equities research analysts forecast that BridgeBio Pharma, Inc. will post -3.67 EPS for the current year.

Hedge Funds Weigh In On BridgeBio Pharma

Several hedge funds have recently made changes to their positions in the business. Jefferies Financial Group Inc. bought a new stake in shares of BridgeBio Pharma in the fourth quarter worth $5,076,000. Mackenzie Financial Corp lifted its position in BridgeBio Pharma by 6.6% during the 4th quarter. Mackenzie Financial Corp now owns 9,505 shares of the company’s stock worth $261,000 after buying an additional 592 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of BridgeBio Pharma during the 4th quarter worth about $109,000. Frazier Life Sciences Management L.P. grew its holdings in shares of BridgeBio Pharma by 1.1% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,800,457 shares of the company’s stock valued at $104,285,000 after acquiring an additional 40,000 shares in the last quarter. Finally, Woodline Partners LP increased its position in shares of BridgeBio Pharma by 132.9% in the fourth quarter. Woodline Partners LP now owns 2,211,521 shares of the company’s stock valued at $60,684,000 after acquiring an additional 1,261,772 shares during the last quarter. 99.85% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on BBIO shares. Evercore ISI lifted their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, December 23rd. Scotiabank boosted their target price on BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Friday, February 21st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $95.00 price target on shares of BridgeBio Pharma in a research report on Friday, February 21st. Bank of America boosted their price objective on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. Finally, Citigroup increased their target price on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Friday, February 21st. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $51.67.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.